Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -303.61% is 28% below its 5-year average of -237.89%, near the high end of its 5-year range (-732.71%–-122.75%).
As of the fiscal period ended Tuesday, June 30, 2026. 7.09% above its 12-month average of -326.78%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -303.61%.
RETURN ON EQUITY (ROE)
-303.61%
RETURN ON EQUITY (ROE) AVG TTM
-326.78%
RETURN ON EQUITY (ROE) AVG 3Y
-250.78%
RETURN ON EQUITY (ROE) AVG 5Y
-237.89%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+7.09%
CURRENT VS 3Y AVG
-21.06%
CURRENT VS 5Y AVG
-27.63%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.56%
median of 737 covered companies
CURRENT VS SECTOR MEDIAN
-630.53%
vs the sector median at left
Biodesix, Inc.
Market Cap
$228.74M
Return on Equity (ROE)
-303.61%
TTM Avg
-326.78%
3Y Avg
-250.78%
5Y Avg
-237.89%
Market Cap
$232.32M
Return on Equity (ROE)
-34.04%
TTM Avg
-95.97%
3Y Avg
-70.55%
5Y Avg
-68.40%
Market Cap
$233.51M
Return on Equity (ROE)
-43.11%
TTM Avg
-35.75%
3Y Avg
-28.47%
5Y Avg
-12.53%
Market Cap
$237.38M
Return on Equity (ROE)
-25.20%
TTM Avg
-25.82%
3Y Avg
5.12%
5Y Avg
5.12%
Market Cap
$234.75M
Return on Equity (ROE)
-1.67%
TTM Avg
19.58%
3Y Avg
23.42%
5Y Avg
29.49%
Market Cap
$223.48M
Return on Equity (ROE)
-31.70%
TTM Avg
-2.04%
3Y Avg
-21.96%
5Y Avg
-21.56%
Market Cap
$235.67M
Return on Equity (ROE)
-27.27%
TTM Avg
-92.43%
3Y Avg
-64.95%
5Y Avg
-57.80%
Market Cap
$235.79M
Return on Equity (ROE)
8.59%
TTM Avg
10.64%
3Y Avg
12.16%
5Y Avg
12.16%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Biodesix, Inc. (BDSX) | $228.74M | -303.61% | -326.78% | -250.78% | -237.89% |
| Vogenx Inc. (VOGX)vs › | $229.03M | N/A | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $232.32M | -34.04% | -95.97% | -70.55% | -68.40% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $233.51M | -43.11% | -35.75% | -28.47% | -12.53% |
| BioAge Labs Inc. (BIOA)vs › | $237.38M | -25.20% | -25.82% | 5.12% | 5.12% |
| SIGA Technologies, Inc. (SIGA)vs › | $234.75M | -1.67% | 19.58% | 23.42% | 29.49% |
| Keros Therapeutics, Inc. (KROS)vs › | $223.48M | -31.70% | -2.04% | -21.96% | -21.56% |
| InflaRx N.V. (IFRX)vs › | $235.67M | -27.27% | -92.43% | -64.95% | -57.80% |
| Utah Medical Products, Inc. (UTMD)vs › | $235.79M | 8.59% | 10.64% | 12.16% | 12.16% |
| Profound Medical Corp. (PROF)vs › | $222.75M | -65.59% | -45.72% | -59.51% | -49.73% |
ROE
-303.6%
ROA
-29.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -303.61% |
| 2026-03-31 | -349.95% |
| 2025-03-31 | -365.44% |
| 2024-12-31 | -205.65% |
| 2024-09-30 | -157.30% |
| 2024-06-30 | -122.75% |
| 2022-12-31 | -317.61% |
| 2022-06-30 | -732.71% |
| 2022-03-31 | -665.52% |
| 2021-12-31 | -218.78% |
| 2021-09-30 | -214.62% |
| 2021-06-30 | -123.16% |
| 2021-03-31 | -78.52% |
| 2020-12-31 | -76.15% |
